PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
May 1, 2009, 00:00
10.1016/S1098-3015(10)73257-5
https://www.valueinhealthjournal.com/article/S1098-3015(10)73257-5/fulltext
Title :
PCN20 THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)73257-5&doi=10.1016/S1098-3015(10)73257-5
First page :
Section Title :
Open access? :
No
Section Order :
676